EssilorLuxottica Unsponsored ADR (OTCMKTS:ESLOY) Given Average Rating of “Moderate Buy” by Analysts

EssilorLuxottica Unsponsored ADR (OTCMKTS:ESLOY – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the company.

Several equities analysts have commented on the stock. The Goldman Sachs Group downgraded shares of EssilorLuxottica from a “buy” rating to a “hold” rating in a research note on Tuesday, July 14th. Zacks Research upgraded EssilorLuxottica from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 18th. Finally, Deutsche Bank Aktiengesellschaft began coverage on EssilorLuxottica in a research note on Tuesday, May 12th. They set a “hold” rating for the company.

Get EssilorLuxottica alerts:

View Our Latest Stock Analysis on EssilorLuxottica

EssilorLuxottica Stock Down 0.4%

Shares of ESLOY opened at $92.70 on Thursday. EssilorLuxottica has a fifty-two week low of $91.44 and a fifty-two week high of $186.81. The firm’s 50 day moving average price is $96.17 and its 200 day moving average price is $109.27. The company has a quick ratio of 0.70, a current ratio of 0.99 and a debt-to-equity ratio of 0.17.

About EssilorLuxottica

(Get Free Report)

EssilorLuxottica SE is a global ophthalmic optics company formed through the 2018 merger of France-based Essilor and Italy-based Luxottica. Headquartered near Paris, the company combines lens manufacturing, frame design and production, brand management and retail operations to provide a vertically integrated offering across the vision care value chain. Its activities span product research and development, manufacturing, wholesale distribution and retailing of spectacles, sunglasses and ophthalmic lenses.

The company’s product portfolio includes prescription and non-prescription lenses, lens coatings and treatments, and an array of eyewear brands and frames.

See Also

• Five stocks we like better than EssilorLuxottica
• Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
• Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
• Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
• Can Tesla’s Flying Roadster Distract From Its Real Risks?

Receive News & Ratings for EssilorLuxottica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EssilorLuxottica and related companies with MarketBeat.com's FREE daily email newsletter.